Allogene Therapeutics Inc. (NASDAQ:ALLO) has announced that it will present preliminary data from the Phase 1 UNIVERSAL ALLO-715 trial at the 62nd Annual American Society of Hematology (ASH) meeting, which will take place on December 5-8, 2020. ALLO-715 is an anti-BCMA AlloCAR T therapy for treating refractory/relapsed multiple myeloma.
Allogene to make a poster presentation of ALLO-316 and ALLO-605
Also preliminary results from the ALLO-316 study which is an AlloCAR T targeting CD70 in AML and ALLO-605 which a BCMA-directed TurboCAR T™ multiple myeloma cell therapy will be presented during the ASH meeting in posters.
Rafael Amado, the Executive VP of Research and Development and Chief Medical Officer of the company, said that they are looking forward to presenting the first initial anti-BCNA AlloCAR T therapy data. Amado said that they believe ALLO-715 will offer insights into how to optimize lymphodepletion and cell does to attain its potential for patients needing readily available treatment alternatives. The preliminary study findings will be vital in informing the trial design of the BCMA platform as Allogene looks to advance ALLO-715 either alone or in combination with a gamma-secretase inhibitor. Allogene also expects to advance its first TurboCAR T clinical candidate ALLO-605.
Patients received 3 dose levels in the UNIVERSAL study
Patients received lymphodepletion (LD) in the initial dose-escalation part if the UNIVERSAL study followed by ALLO-715 at one of 3 dose levels in 3+3 dose escalations design. When the company has the abstract data cutoff in July 2020 already two LD regimens were being studied. The first regimen was Fludarabine 90mg/m2, Cyclophosphamide 900mg/m2 ALLO-647 39 mg spread over three days. The other dose regimen was Cyclophosphamide 900 mg/m2 and ALLO-647 49 mg over three days.
The data the company will present in the ASH abstract includes initial data on the first 15 patients evaluated for efficacy and who received escalating ALLO-715 doses and lower ALLO-647 dose. The trial didn’t allow bride therapy, and the patients were in advanced stages of the disease with an average of 5 previous therapy lines.